Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Stefanzl G, Sadovnik I, Berger D, Keller A, Hauswirth A, Hoermann G, Willmann M, Rülicke T, Sill H, Sperr WR, Mannhalter C, Melo JV, Jäger U, Sexl V, Valent P.

Neoplasia. 2018 Jun;20(6):632-642. doi: 10.1016/j.neo.2018.04.004. Epub 2018 May 15.

2.

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M, Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E, Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P.

Haematologica. 2018 May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018 Feb 8.

3.

Variability of PD-L1 expression in mastocytosis.

Hatch EW, Geeze MB, Martin C, Salama ME, Hartmann K, Eisenwort G, Blatt K, Valent P, Gotlib J, Lee JH, Chen L, Ward HH, Lidke DS, George TI.

Blood Adv. 2018 Feb 13;2(3):189-199. doi: 10.1182/bloodadvances.2017011551.

4.

Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments.

Gadermaier E, Marth K, Lupinek C, Campana R, Hofer G, Blatt K, Smiljkovic D, Roder U, Focke-Tejkl M, Vrtala S, Keller W, Valent P, Valenta R, Flicker S.

Allergy. 2018 Jul;73(7):1425-1435. doi: 10.1111/all.13394. Epub 2018 Feb 20.

5.

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P.

Leukemia. 2018 Apr;32(4):1016-1022. doi: 10.1038/leu.2017.338. Epub 2017 Nov 29.

6.

Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.

Liebowitz MR, Careri J, Blatt K, Draine A, Morita J, Moran M, Hanover R.

Depress Anxiety. 2017 Dec;34(12):1164-1172. doi: 10.1002/da.22702. Epub 2017 Nov 22.

PMID:
29166552
7.

Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study.

Eckl-Dorna J, Fröschl R, Lupinek C, Kiss R, Gattinger P, Marth K, Campana R, Mittermann I, Blatt K, Valent P, Selb R, Mayer A, Gangl K, Steiner I, Gamper J, Perkmann T, Zieglmayer P, Gevaert P, Valenta R, Niederberger V.

Allergy. 2018 May;73(5):1003-1012. doi: 10.1111/all.13343. Epub 2017 Dec 12.

8.

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

Stefanzl G, Berger D, Cerny-Reiterer S, Blatt K, Eisenwort G, Sperr WR, Hoermann G, Lind K, Hauswirth AW, Bettelheim P, Sill H, Melo JV, Jäger U, Valent P.

Oncotarget. 2017 Jun 28;8(40):67709-67722. doi: 10.18632/oncotarget.18810. eCollection 2017 Sep 15.

9.

Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Valent P, Akin C, Hartmann K, George TI, Sotlar K, Peter B, Gleixner KV, Blatt K, Sperr WR, Manley PW, Hermine O, Kluin-Nelemans HC, Arock M, Horny HP, Reiter A, Gotlib J.

Ann Oncol. 2017 Oct 1;28(10):2367-2376. doi: 10.1093/annonc/mdx290. Review.

PMID:
28945834
10.

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P.

Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8.

11.

Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.

Sadovnik I, Herrmann H, Eisenwort G, Blatt K, Hoermann G, Mueller N, Sperr WR, Valent P.

Exp Hematol. 2017 Jul;51:17-24. doi: 10.1016/j.exphem.2017.04.003. Epub 2017 Apr 27. Review.

12.

BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils.

Smiljkovic D, Blatt K, Stefanzl G, Dorofeeva Y, Skrabs C, Focke-Tejkl M, Sperr WR, Jaeger U, Valenta R, Valent P.

Allergy. 2017 Nov;72(11):1666-1676. doi: 10.1111/all.13166. Epub 2017 Apr 20.

13.

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy.

Lupinek C, Derfler K, Lee S, Prikoszovich T, Movadat O, Wollmann E, Cornelius C, Weber M, Fröschl R, Selb R, Blatt K, Smiljkovic D, Schoder V, Cervenka R, Plaichner T, Stegfellner G, Huber H, Henning R, Kozik-Jaromin J, Perkmann T, Niederberger V, Petkov V, Valent P, Gauly A, Leinenbach HP, Uhlenbusch-Koerwer I, Valenta R.

EBioMedicine. 2017 Mar;17:119-133. doi: 10.1016/j.ebiom.2017.02.007. Epub 2017 Feb 12.

14.

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.

Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, Sperr WR, Bettelheim P, Akin C, Bauer K, George TI, Hadzijusufovic E, Wolf D, Gotlib J, Mahon FX, Metcalfe DD, Horny HP, Arock M.

Leukemia. 2017 Apr;31(4):788-797. doi: 10.1038/leu.2017.15. Epub 2017 Jan 16. Review.

PMID:
28090091
15.

Modifying the risk of recurrent preterm birth: influence of trimester-specific changes in smoking behaviors.

Wallace JL, Aland KL, Blatt K, Moore E, DeFranco EA.

Am J Obstet Gynecol. 2017 Mar;216(3):310.e1-310.e8. doi: 10.1016/j.ajog.2016.11.1034. Epub 2016 Nov 18.

PMID:
27871837
16.

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.

Zieglmayer P, Focke-Tejkl M, Schmutz R, Lemell P, Zieglmayer R, Weber M, Kiss R, Blatt K, Valent P, Stolz F, Huber H, Neubauer A, Knoll A, Horak F, Henning R, Valenta R.

EBioMedicine. 2016 Sep;11:43-57. doi: 10.1016/j.ebiom.2016.08.022. Epub 2016 Aug 20.

17.

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.

Blatt K, Herrmann H, Stefanzl G, Sperr WR, Valent P.

Oncotarget. 2016 Oct 4;7(40):65627-65642. doi: 10.18632/oncotarget.11593.

18.

Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen.

Resch Y, Blatt K, Malkus U, Fercher C, Swoboda I, Focke-Tejkl M, Chen KW, Seiberler S, Mittermann I, Lupinek C, Rodriguez-Dominguez A, Zieglmayer P, Zieglmayer R, Keller W, Krzyzanek V, Valent P, Valenta R, Vrtala S.

PLoS One. 2016 Aug 22;11(8):e0160641. doi: 10.1371/journal.pone.0160641. eCollection 2016.

19.

Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence.

Gilgun-Sherki Y, Eliaz RE, McCann DJ, Loupe PS, Eyal E, Blatt K, Cohen-Barak O, Hallak H, Chiang N, Gyaw S.

Drug Alcohol Depend. 2016 Sep 1;166:13-20. doi: 10.1016/j.drugalcdep.2016.05.019. Epub 2016 May 28.

20.

Relationship of trimester-specific smoking patterns and risk of preterm birth.

Moore E, Blatt K, Chen A, Van Hook J, DeFranco EA.

Am J Obstet Gynecol. 2016 Jul;215(1):109.e1-6. doi: 10.1016/j.ajog.2016.01.167. Epub 2016 Jan 28.

21.

Sterilization of Lung Matrices by Supercritical Carbon Dioxide.

Balestrini JL, Liu A, Gard AL, Huie J, Blatt KM, Schwan J, Zhao L, Broekelmann TJ, Mecham RP, Wilcox EC, Niklason LE.

Tissue Eng Part C Methods. 2016 Mar;22(3):260-9. doi: 10.1089/ten.TEC.2015.0449. Epub 2016 Jan 29.

22.

Factors Associated with Smoking Cessation in Pregnancy.

Moore E, Blatt K, Chen A, Van Hook J, DeFranco EA.

Am J Perinatol. 2016 May;33(6):560-8. doi: 10.1055/s-0035-1570319. Epub 2015 Dec 21.

23.

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, Hoermann G, Greiner G, Blatt K, Peter B, Stefanzl G, Berger D, Bilban M, Herndlhofer S, Sill H, Sperr WR, Streubel B, Mannhalter C, Holyoake TL, Sexl V, Valent P.

Clin Cancer Res. 2016 Apr 15;22(8):2051-61. doi: 10.1158/1078-0432.CCR-15-0767. Epub 2015 Nov 25.

24.

Mechanism of Bacillus subtilis spore inactivation by and resistance to supercritical CO2 plus peracetic acid.

Setlow B, Korza G, Blatt KM, Fey JP, Setlow P.

J Appl Microbiol. 2016 Jan;120(1):57-69. doi: 10.1111/jam.12995. Epub 2015 Dec 9.

25.

Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.

Campana R, Moritz K, Marth K, Neubauer A, Huber H, Henning R, Blatt K, Hoermann G, Brodie TM, Kaider A, Valent P, Sallusto F, Wöhrl S, Valenta R.

J Allergy Clin Immunol. 2016 Feb;137(2):601-609.e8. doi: 10.1016/j.jaci.2015.08.042. Epub 2015 Oct 28.

26.

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G, Stefanzl G, Hoermann G, Mayerhofer M, Schneeweiss M, Knapp S, Rülicke T, Hadzijusufovic E, Bauer K, Smiljkovic D, Willmann M, Reiter A, Horny HP, Valent P.

Blood. 2015 Dec 24;126(26):2832-41. doi: 10.1182/blood-2015-03-637728. Epub 2015 Oct 20. Erratum in: Blood. 2018 Mar 22;131(12 ):1390.

27.

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.

Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P.

Leukemia. 2016 Feb;30(2):464-72. doi: 10.1038/leu.2015.242. Epub 2015 Sep 9.

28.

Epitope specificity determines cross-protection of a SIT-induced IgG4 antibody.

Gadermaier E, James LK, Shamji MH, Blatt K, Fauland K, Zieglmayer P, Garmatiuk T, Focke-Tejkl M, Villalba M, Beavil R, Keller W, Valent P, Durham SR, Gould HJ, Flicker S, Valenta R.

Allergy. 2016 Jan;71(1):36-46. doi: 10.1111/all.12710. Epub 2015 Sep 30.

29.

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.

Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Müllauer L, Schwaab J, Hoffmann T, Bradner JE, Radia D, Sperr WR, Hoermann G, Reiter A, Horny HP, Zuber J, Arock M, Valent P.

Leukemia. 2015 Nov;29(11):2230-7. doi: 10.1038/leu.2015.138. Epub 2015 Jun 9.

30.

Association of reported trimester-specific smoking cessation with fetal growth restriction.

Blatt K, Moore E, Chen A, Van Hook J, DeFranco EA.

Obstet Gynecol. 2015 Jun;125(6):1452-9. doi: 10.1097/AOG.0000000000000679.

31.

Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC, Valent P.

J Hematol Oncol. 2015 Feb 25;8:16. doi: 10.1186/s13045-015-0113-9. Review.

32.

Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy.

Linhart B, Focke-Tejkl M, Weber M, Narayanan M, Neubauer A, Mayrhofer H, Blatt K, Lupinek C, Valent P, Valenta R.

J Immunol. 2015 Apr 15;194(8):4008-18. doi: 10.4049/jimmunol.1400402. Epub 2015 Mar 18.

33.

Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers.

Madritsch C, Eckl-Dorna J, Blatt K, Ellinger I, Kundi M, Niederberger V, Valent P, Valenta R, Flicker S.

J Allergy Clin Immunol. 2015 Aug;136(2):490-3.e11. doi: 10.1016/j.jaci.2015.01.006. Epub 2015 Mar 11. No abstract available.

34.

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.

Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R, Stegfellner G, Maderegger B, Hauer M, Stolz F, Niederberger V, Marth K, Eckl-Dorna J, Weiss R, Thalhamer J, Blatt K, Valent P, Valenta R.

J Allergy Clin Immunol. 2015 May;135(5):1207-7.e1-11. doi: 10.1016/j.jaci.2014.09.012. Epub 2014 Nov 13.

35.

DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.

Valent P, Sadovnik I, Ráčil Z, Herrmann H, Blatt K, Cerny-Reiterer S, Eisenwort G, Lion T, Holyoake T, Mayer J.

Eur J Clin Invest. 2014 Dec;44(12):1239-45. doi: 10.1111/eci.12368. Review.

PMID:
25371066
36.

Der p 11 is a major allergen for house dust mite-allergic patients suffering from atopic dermatitis.

Banerjee S, Resch Y, Chen KW, Swoboda I, Focke-Tejkl M, Blatt K, Novak N, Wickman M, van Hage M, Ferrara R, Mari A, Purohit A, Pauli G, Sibanda EN, Ndlovu P, Thomas WR, Krzyzanek V, Tacke S, Malkus U, Valent P, Valenta R, Vrtala S.

J Invest Dermatol. 2015 Jan;135(1):102-109. doi: 10.1038/jid.2014.271. Epub 2014 Aug 7.

37.

Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.

Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, Herndlhofer S, Streubel B, Rabitsch W, Sperr WR, Mayerhofer M, Rülicke T, Valent P.

Clin Cancer Res. 2014 Jul 1;20(13):3589-602. doi: 10.1158/1078-0432.CCR-13-2811. Epub 2014 May 5.

38.

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.

Herrmann H, Sadovnik I, Cerny-Reiterer S, Rülicke T, Stefanzl G, Willmann M, Hoermann G, Bilban M, Blatt K, Herndlhofer S, Mayerhofer M, Streubel B, Sperr WR, Holyoake TL, Mannhalter C, Valent P.

Blood. 2014 Jun 19;123(25):3951-62. doi: 10.1182/blood-2013-10-536078. Epub 2014 Apr 28.

39.

CD52 is a molecular target in advanced systemic mastocytosis.

Hoermann G, Blatt K, Greiner G, Putz EM, Berger A, Herrmann H, Cerny-Reiterer S, Gleixner KV, Walz C, Hoetzenecker K, Müllauer L, Reiter A, Sotlar K, Sexl V, Valent P, Mayerhofer M.

FASEB J. 2014 Aug;28(8):3540-51. doi: 10.1096/fj.14-250894. Epub 2014 Apr 23.

PMID:
24760752
40.

Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine.

Banerjee S, Weber M, Blatt K, Swoboda I, Focke-Tejkl M, Valent P, Valenta R, Vrtala S.

J Immunol. 2014 May 15;192(10):4867-75. doi: 10.4049/jimmunol.1400064. Epub 2014 Apr 14.

41.

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.

Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, Blatt K, Hadzijusufovic E, Jeanningros S, Blanc C, Legarff-Tavernier M, Chapiro E, Nguyen-Khac F, Subra F, Bonnemye P, Dubreuil P, Desplat V, Merle-Béral H, Willmann M, Rülicke T, Valent P, Arock M.

Blood. 2014 Jul 3;124(1):111-20. doi: 10.1182/blood-2013-10-534685. Epub 2014 Mar 27.

42.

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H.

Valent P, Blatt K, Eisenwort G, Herrmann H, Cerny-Reiterer S, Thalhammer R, Müllauer L, Hoermann G, Sadovnik I, Schwarzinger I, Sperr WR, Mannhalter C, Horny HP.

Leuk Res Rep. 2013 Nov 26;3(1):8-13. doi: 10.1016/j.lrr.2013.11.001. eCollection 2014.

43.

Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction.

Curin M, Weber M, Thalhamer T, Swoboda I, Focke-Tejkl M, Blatt K, Valent P, Marth K, Garmatiuk T, Grönlund H, Thalhamer J, Spitzauer S, Valenta R.

Clin Exp Allergy. 2014 Jun;44(6):882-94. doi: 10.1111/cea.12294.

44.

Possible therapeutic potential of a recombinant group 2 grass pollen allergen-specific antibody fragment.

Gadermaier E, Flicker S, Blatt K, Valent P, Valenta R.

Allergy. 2014 Feb;69(2):261-4. doi: 10.1111/all.12315. Epub 2013 Nov 20.

45.

The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.

Karlic H, Herrmann H, Varga F, Thaler R, Reitermaier R, Spitzer S, Ghanim V, Blatt K, Sperr WR, Valent P, Pfeilstöcker M.

Crit Rev Oncol Hematol. 2014 Apr;90(1):1-16. doi: 10.1016/j.critrevonc.2013.10.003. Epub 2013 Oct 12. Review.

PMID:
24183913
46.

Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5.

Focke-Tejkl M, Campana R, Reininger R, Lupinek C, Blatt K, Valent P, Pavkov-Keller T, Keller W, Valenta R.

J Allergy Clin Immunol. 2014 Mar;133(3):836-45.e11. doi: 10.1016/j.jaci.2013.08.038. Epub 2013 Oct 31.

PMID:
24182774
47.

A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.

Rix U, Colinge J, Blatt K, Gridling M, Remsing Rix LL, Parapatics K, Cerny-Reiterer S, Burkard TR, Jäger U, Melo JV, Bennett KL, Valent P, Superti-Furga G.

PLoS One. 2013 Oct 10;8(10):e77155. doi: 10.1371/journal.pone.0077155. eCollection 2013.

48.

Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy.

Garmatiuk T, Swoboda I, Twardosz-Kropfmüller A, Dall'Antonia F, Keller W, Singh MB, Bhalla PL, Okada T, Toriyama K, Weber M, Ghannadan M, Sperr WR, Blatt K, Valent P, Klein B, Niederberger V, Curin M, Balic N, Spitzauer S, Valenta R.

Immunobiology. 2013 Sep;218(9):1155-1165. doi: 10.1016/j.imbio.2013.04.006. Epub 2013 Apr 24.

49.

Prevalence of benign paroxysmal positional vertigo in the young adult population.

Kerrigan MA, Costigan MF, Blatt KJ, Mathiason MA, Domroese ME.

PM R. 2013 Sep;5(9):778-85. doi: 10.1016/j.pmrj.2013.05.010. Epub 2013 May 22.

PMID:
23707569
50.

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.

Gleixner KV, Peter B, Blatt K, Suppan V, Reiter A, Radia D, Hadzijusufovic E, Valent P.

Haematologica. 2013 Sep;98(9):1450-7. doi: 10.3324/haematol.2012.079202. Epub 2013 Mar 28.

Supplemental Content

Support Center